Salvianic acid A ameliorates atherosclerosis through metabolic-dependent anti-EndMT pathway and repression of TGF-β/ALK5 signaling
Phytomedicine · 2025
DOI: 10.1016/j.phymed.2024.156307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Yijun Gao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai 411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, PR China. Hauptthemen laut MEDLINE: Atherosclerosis, Receptor, Transforming Growth Factor-beta Type I, Transforming Growth Factor beta, Lactates. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Pudong New Area Health Commission.
Abstract (Originalsprache)
BACKGROUND: Endothelial-to-mesenchymal transition (EndMT) has been identified as a key factor to the initiation and progression of the pathogenesis of atherosclerosis (AS). Salvianic acid A (SAAS) is the primary water-soluble bioactive ingredient found in Salvia miltiorrhiza, is renowned for its therapeutic effects on cardiovascular diseases. However, the efficacy and mechanisms of SAAS in treating EndMT-induced AS remain underexplored. PURPOSE: This study aimed to investigate the role SAAS in reversing EndMT process to impede AS development. METHODS: We used a murine model of cholesterol-rich and high-fat diet-induced AS in ApoE-/- mice to evaluate the effect of SAAS on EndMT during AS progression in vivo. The biological effects of SAAS on EndMT-induced HUVEC cells were also detected by transcriptome sequencing (RNA-seq). Mechanistic exploration was carried out using omics data mining and screening, gene knockout experiments, gene expression, protein expression, and localization of key gene expression in animal lesion areas. RESULTS: We found that SAAS treatment significantly alleviated EndMT injury in the AS mice model and also improved aortic root lesions and dyslipidemia. Furthermore, pre-treatment with SAAS effectively inhibited the EndMT in HUVEC cells, as evidenced by maintained endothelial cell morphology and reduced cell migration ability, as well as elevated CD31 and decreased α-SMA. RNA sequencing data indicated that key differentially expressed genes were mainly enriched in metabolism-related and TGF-β receptor signaling pathways. The metabolic regulator PDK4 and profibrotic TGF-β receptor ALK5 were identified specifically. Subsequently, RT-qPCR and western blot results demonstrated that SAAS notably increased metabolic regulator PDK4 and decreased profibrotic TGF-β receptor ALK5 in EndMT-induced HUVEC cells. Moreover, siRNA-directed PDK4 inhibition resulted in EndMT induction and SAAS mediated the suppression of EndMT in a PDK4-dependent manner. Additionally, SAAS partially reduced the TGF-β receptor ALK5 expression. Furthermore, ApoE-/- AS mice with SAAS treatment displayed downregulation of ALK5 and upregulation of PDK4 with reduced EndMT during AS. CONCLUSION: This investigation demonstrated that SAAS improved AS through metabolic-dependent anti-EndMT pathway and repression of profibrotic TGF-β receptor signaling, thereby providing SAAS as a promising therapeutic candidate for managing AS and EndMT-related disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai 411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, PR China.
- Department of Pharmacy, Shanghai Pudong New Area People's Hospital, Shanghai, 201200, PR China.
- Shenzhen Medicines and Health Products IMP. & EXP. Co., Ltd, Shenzhen, PR China.
- Department of Infection Control, Hangzhou Third People's Hospital, Affiliated Hangzhou Dermatology Hospital, West Lake Rd 38, Hangzhou, 310009, PR China. Electronic address: Jjianfang2000@163.com.
- Shanghai 411 Hospital, Shanghai, 200081, PR China. Electronic address: 1243052073@qq.com.
- Shanghai 411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, PR China; Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital…
Förderung
- National Natural Science Foundation of China
- Shanghai Pudong New Area Health Commission
Zitieren
APA
Gao, Y., Ye, F., Dong, Y., Wang, T., Xiong, L., Chen, T., Wang, Y., Liu, X., Zhang, Y., Qiu, Z., Jiang, J., Liu, X., Hu, Q., & Zhang, C. (2025). Salvianic acid A ameliorates atherosclerosis through metabolic-dependent anti-EndMT pathway and repression of TGF-β/ALK5 signaling. Phytomedicine. https://doi.org/10.1016/j.phymed.2024.156307
Vancouver
Gao Y, Ye F, Dong Y, Wang T, Xiong L, Chen T, et al. Salvianic acid A ameliorates atherosclerosis through metabolic-dependent anti-EndMT pathway and repression of TGF-β/ALK5 signaling. Phytomedicine. 2025. doi:10.1016/j.phymed.2024.156307
BibTeX
@article{Gao2025,
author = {Gao, Yijun and Ye, Fei and Dong, Yafen and Wang, Tingfang and Xiong, Liyan and Chen, Ting and Wang, Yun and Liu, Xiaoyan and Zhang, Yunan and Qiu, Zheng and Jiang, Jianfang and Liu, Xijun and Hu, Qingxun and Zhang, Chuan},
title = {Salvianic acid A ameliorates atherosclerosis through metabolic-dependent anti-EndMT pathway and repression of TGF-β/ALK5 signaling},
journal = {Phytomedicine},
year = {2025},
doi = {10.1016/j.phymed.2024.156307}
}
EUVIMED